Tyche Wealth Partners LLC Buys 50,864 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

Tyche Wealth Partners LLC increased its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 23.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 266,766 shares of the biotechnology company’s stock after acquiring an additional 50,864 shares during the period. Tyche Wealth Partners LLC’s holdings in Coherus BioSciences were worth $368,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Coherus BioSciences by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 2,565,145 shares of the biotechnology company’s stock worth $2,668,000 after purchasing an additional 182,914 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Coherus BioSciences by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 964,327 shares of the biotechnology company’s stock valued at $1,003,000 after buying an additional 116,217 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in Coherus BioSciences by 344.1% during the third quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company’s stock worth $967,000 after buying an additional 720,672 shares during the last quarter. AQR Capital Management LLC acquired a new position in Coherus BioSciences during the second quarter worth $1,246,000. Finally, XTX Topco Ltd raised its position in Coherus BioSciences by 74.5% during the third quarter. XTX Topco Ltd now owns 473,517 shares of the biotechnology company’s stock worth $492,000 after acquiring an additional 202,084 shares in the last quarter. 72.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Coherus BioSciences in a research note on Thursday, January 23rd. StockNews.com cut Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th. Finally, Robert W. Baird lifted their price objective on shares of Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Coherus BioSciences presently has an average rating of “Moderate Buy” and an average target price of $5.38.

Coherus BioSciences Price Performance

CHRS opened at $1.13 on Friday. The business has a fifty day simple moving average of $1.44 and a 200 day simple moving average of $1.24. Coherus BioSciences, Inc. has a 1 year low of $0.66 and a 1 year high of $2.87. The company has a market capitalization of $130.96 million, a PE ratio of -14.13 and a beta of 0.81.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.